Royal Bank Of Canada Reaffirms Outperform Rating for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK)‘s stock had its “outperform” rating reiterated by investment analysts at Royal Bank Of Canada in a report released on Wednesday,Benzinga reports. They presently have a $142.00 price objective on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 12.48% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on MRK. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday. Bank of America increased their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective on the stock. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Scotiabank upped their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $132.11.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $126.24 on Wednesday. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $130.29. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The stock has a market cap of $311.80 billion, a P/E ratio of 35.59, a PEG ratio of 2.71 and a beta of 0.19. The business’s 50-day moving average price is $117.95 and its two-hundred day moving average price is $115.88.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business posted $2.22 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 5.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors have recently bought and sold shares of the stock. Somerset Trust Co grew its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the last quarter. Stonebridge Financial Group LLC boosted its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after buying an additional 81 shares during the period. Chesapeake Wealth Management boosted its position in Merck & Co., Inc. by 0.6% during the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after buying an additional 87 shares during the period. South Plains Financial Inc. grew its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after acquiring an additional 89 shares during the last quarter. Finally, Syverson Strege & Co grew its holdings in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after acquiring an additional 90 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.